Real-World Therapy Management and Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United States

BackgroundCombination axitinib plus pembrolizumab is a standard of care in the first-line treatment of patients with advanced clear cell renal cell carcinoma (RCC). This analysis describes the clinical characteristics, treatment management and outcomes of patients receiving first-line (1L) axitinib...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Yousef Zakharia, Despina Thomaidou, Benjamin Li, Gordon Siu, Rebecca Levin, Anna Vlahiotis, Dharanija Rao, Giovanni Zanotti
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2022-05-01
Colecção:Frontiers in Oncology
Assuntos:
axitinib
combination
renal cell carcinoma
real-world
therapy management
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fonc.2022.861189/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados